Titre :

Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: the platum trial

Auteur(s) :

Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Devos, Patrick [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Houillier, Caroline [Auteur]

Cartalat, Stephanie [Auteur]
Service de neuro-oncologie [Hôpital Pierre Wertheimer - HCL]
Chinot, Olivier [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Di Stefano, Anna Luisa [Auteur]

Lepage, Clement [Auteur]
Reyns, Nicolas [Auteur]
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Dubois, François [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Weller, Michael [Auteur]
University hospital of Zurich [Zurich]

Titre de la revue :

Neurology

Nom court de la revue :

Neurology

Date de publication :

2019-10-04

ISSN :

1526-632X

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

OBJECTIVE: To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma. METHODS: In the PLATUM phase II open-label, ...
Lire la suite >OBJECTIVE: To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma. METHODS: In the PLATUM phase II open-label, multicenter, single-arm trial, patients diagnosed with Common Terminology Criteria for Adverse Events grade 3 or 4 thrombocytopenia during chemoradiotherapy received weekly subcutaneous romiplostim injections. PLATUM aimed at demonstrating that the percentage of thrombocytopenic patients treated with romiplostim able to complete 6 cycles of maintenance temozolomide chemotherapy exceeded 10% (pp RESULTS: Twenty patients were enrolled in step 1. Median age was 61 years (range 33-73). Twelve patients received 6 temozolomide cycles, corresponding to a success rate of 60% (95% confidence interval 36%-81%). Four patients discontinued temozolomide because they did not respond to romiplostim, 2 for progression, and 2 for adverse events unrelated to romiplostim. CONCLUSIONS: The thrombopoietin receptor agonist romiplostim improves exposure to chemotherapy in patients with glioblastoma experiencing temozolomide-induced thrombocytopenia. NCT02227576. METHODS: This study provides Class IV evidence that for patients with glioblastoma and thrombocytopenia, romiplostim is effective for the secondary prophylaxis of temozolomide-induced thrombocytopenia.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
INSERM
Inserm
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Date de dépôt :

2019-12-09T16:47:49Z
2020-01-17T15:30:50Z
2021-05-31T08:43:00Z
2023-04-21T09:51:33Z